cancers

Oncology

CAR-NK cell therapies are frequently misunderstood, despite growing clinical and preclinical data supporting their potential.

News

In its third big licensing deal of the week, Eli Lilly has tapped RNA-editing specialist Ascidian for kidney disease therapies in a $1.9bn alliance.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.